SHIM
MLYS icon

Stone House Investment Management’s Mineralys Therapeutics MLYS Stock Holding History

Stone House Investment Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108 Hold
4
– – ﹤0.01% 1281
2026
Q1 		$108 Buy
+4
New +$117 ﹤0.01% 1005

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Stone House Investment Management's MLYS Position: Q2 2026 in Review

Stone House Investment Management held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 4 shares worth $108. The position accounts for ﹤0.01% of the portfolio, ranked #1281.

Stone House Investment Management first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Stone House Investment Management held 4 shares of Mineralys Therapeutics worth $108 as of Q2 2026.
  • Stone House Investment Management left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1281 holding.
  • Stone House Investment Management first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.